Concomitant short- and long-duration response to levodopa in the 6-OHDA-lesioned rat: A behavioural and molecular study

European Journal of Neuroscience

Volumn 25, Issue 1, 2007, Pages 259-269

  Marin, C ^a,c   Aguilar, E ^a   Mengod, G ^a   Cortes R ^a   Obeso, J A ^b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

6 hydroxydopamine; Basal ganglia; Dynorphin; Enkephalin; Parkinson's disease

Indexed keywords

ADENOSINE A2A RECEPTOR; BENSERAZIDE; CYTOCHROME C OXIDASE; DOPAMINE 3 RECEPTOR; GLUTAMATE DECARBOXYLASE; LEVODOPA METHYL ESTER; MESSENGER RNA; MOLECULAR MARKER; OXIDOPAMINE; PREPRODYNORPHIN; SODIUM CHLORIDE;

AKINESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CHEMICAL MODIFICATION; CIRCLING BEHAVIOR; CONTROLLED STUDY; DRUG RESPONSE; DRUG WITHDRAWAL; FORELIMB; GENE EXPRESSION; LONG TERM CARE; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSONISM; PRIORITY JOURNAL; RAT; RECEPTOR GENE; STATISTICAL SIGNIFICANCE; SUBSTANTIA NIGRA; SUBSTANTIA NIGRA PARS RETICULATA; SUBTHALAMIC NUCLEUS; TREATMENT DURATION; TREATMENT OUTCOME;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN INJURIES; CORPUS STRIATUM; DOPAMINE AGENTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LEVODOPA; MALE; MOTOR ACTIVITY; NERVE TISSUE PROTEINS; OXIDOPAMINE; PSYCHOMOTOR PERFORMANCE; RATS; RATS, SPRAGUE-DAWLEY; ROTAROD PERFORMANCE TEST; TIME FACTORS;

EID: 33846264541     PISSN: 0953816X     EISSN: 14609568     Source Type: Journal    
DOI: 10.1111/j.1460-9568.2006.05265.x     Document Type: Article

References (60)

1. Andersson, M., Hilbertson, A. & Cenci, M.A. (1999) Striatal fos B expression is causally linked with L-Dopa-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol. Dis., 6, 461-474.
2. Andersson, M., Westin, J.E., Cenci, M. & A. (2003) Time course of striatal delta-FosB-like immunoreactivity and prodynorphin mRNA levels after discontinuation of chronic dopaminomimetic treatment. Eur. J. Neurosci., 17, 661-666.
3. Aubert, I., Guigoni, C., Hâkansson, K., Qin, L., Dovero, S., Barthe, N., Bioulac, B.H., Gross, C.E., Fisone, G., Bloch, B. & Bezard, E. (2005) Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann. Neurol., 57, 17-26.
4. Barbato, L., Stocchi, F., Monge, A., Vacca, L., Ruggueri, S., Nordera, G. & Marsden, C.D. (1997) The long-duration action of levodopa may be due to a post-synaptic effect. Clin. Neuropharmacol., 20, 394-401.
5. Bezard, E., Ferry, S., Mach, U., Stark, H., Leriche, L., Boraud, T., Gross, C.E. & Sokoloff, P. (2003) Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat. Med., 9, 762-767.
6. Bezard, E., Ravenscroft, P., Gross, C.E., Crossman, A.R. & Brotchie, J.M. (2001) Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine monkeys. Neurobiol. Dis., 8, 343-350.
7. Bordet, R., Ridray, S., Carboni, S., Diaz, J., Sokoloff, P. & Schwartz, J.C. (1997) Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc. Natl Acad. Sci. USA, 94, 3363-3367.
8. Bordet, R., Ridray, S., Schwartz, J.C. & Sokoloff, P. (2000) Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine lesioned rats. Eur. J. Neurosci., 12, 2117-2123.
9. 2A antagonist CSC with an increase in striatal preprodynorphin mRNA expression in 6-OHDA-lesioned rats. Synapse, 59, 435-444.
10. 2A receptor blockade plus L-Dopa in dopamine-denervated rats. Synapse, 44, 166-174.
11. Cenci, M.A., Lee, C.S. & Björklund, A. (1998) L-Dopa-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci., 10, 2694-2706.
12. Chen, L., Togasaki, D.M., Langston, J.W., DiMonte, D.A. & Quik, M. (2005) Enhanced striatal opioid receptor-mediated G-protein activation in L-Dopatreated monkeys. Neuroscience, 132, 409-420.
13. Duty, S., Henry, B., Crossman, A.R. & Brotchie, J.M. (1998) Topographical organization of opioid peptide precursor gene expression following repeated apomorphine treatment in the 6-hydroxydopamine-lesioned rat. Exp. Neurol., 150, 223-234.
14. Engber, T.M., Papa, S.M., Boldry, R.C. & Chase, T.N. (1994) NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport, 5, 2586-2588.
15. Gerfen, C.R., Engber, T.M., Mahan, L.C., Susel, Z., Chase, T.N., Monsma, F.J., Sibley, D. & R. (1990) D-1 and D-2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science, 250, 1429-1432.
16. Gerfen, C.R., McGinty, J.F. & Young, W.S. 3rd (1991) Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis. J. Neurosci., 11, 1016-1031.
17. Guigoni, C., Aubert, I., Gurevich, V.V., Benovic, J.L., Ferry, S., Mach, U., Stark, H., Leriche, L., Hakansson, K., Bioulac, B.H., Gross, C.E., Sokoloff, P., Fisone, G., Gurevich, E.V., Bloch, B. & Bezard, E. (2005) Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. Parkinsonism Related Dis., 11, S25-S29.
18. Henry, B., Crossman, A.R. & Brotchie, J.M. (1998) Characterization of enhanced behavioral responses to L-Dopa following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp. Neurol., 151, 334-342.
19. Henry, B., Crossman, A.R. & Brotchie, J.M. (1999) Effect of repeated L-Dopa, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp. Neurol., 155, 204-220.
20. 2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J. Comp. Neurol., 431, 331-346.
21. 2A antagonists to the treatment of Parkinsons's disease: concluding remarks. In Kase, H., Richardson, P.J. & Jenner, P. (Eds), Adenosine Receptors and Parkinson's Disease. Academic Press, London, pp. 267-273.
22. Jolkkonen, J., Granata, R., Jenner, P. & Marsden, C.D. (1995) Acute and subchronic effects of dopamine agonists on neuropeptide gene expression in the rat striatum. Neuropeptides, 29, 109-114.
23. 2A receptor gene expression in the normal striatum and after 6-OH-dopamine lesion. J. Neural Transm., 107, 851-859.
24. Lee, E.A., Lee, W.Y., Kim, Y.S. & Kang, U.J. (2003) The effects of chronic L-Dopa therapy on pharmacodynamic parameters in a rat model of motor response fluctuations. Exp. Neurol., 184, 304-312.
25. Levesque, D., Martres, M.-P., Diaz, J., Griffon, N., Lammers, C.H., Sokoloff, P. & Schwartz, J.C. (1995) A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. Proc. Natl Acad. Sci. USA, 92, 1719-1723.
26. Marin, C., Aguilar, E., Bonastre, M., Tolosa, E. & Obeso, J.A. (2005) Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats. Exp. Neurol., 192, 184-193.
27. Marin, C., Jiménez, A., Vila, M., Bonastre, M., Hirsch, E.C., Agid, Y. & Tolosa, E. (2001) LY293558, an AMPA glutamate receptor antagonist prevents and reverses levodopa-induced motor fluctuations in parkinsonian rats. Synapse, 42, 40-47.
28. Marin, C., Papa, S., Engber, T.M., Bonastre, M., Tolosa, E. & Chase, T.N. (1996) MK801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Res., 736, 202-205.
29. Morelli, M., Fenu, S., Pinna, A. & Di Chiara, G. (1994) Adenosine A2 receptors interact negatively with dopamine D1 and D2 receptors in unilaterally 6-hydroxydopamine rats. Eur. J. Pharmacol., 251, 21-25.
30. Morissette, M., Goulet, M., Soghomonian, J.J., Blanchet, P.J., Calon, F., Bedard, P.J. & DiPaolo, T. (1997) Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-Dopa therapy. Brain Res. Mol. Brain Res., 49, 55-62.
31. Morissette, M., Grondin, R., Goulet, M., Bedard, P.J. & Di Paolo, T. (1999) Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists. J. Neurochem., 72, 682-692.
32. Muenter, M.D. & Tyce, G.M. (1971) L-Dopa therapy of Parkinson's disease plasma 1-dopa concentration, therapeutic response, and side effects. Mayo Clinic Proc., 46, 231-239.
33. Nielsen, K.M. & Soghomonian, J. (2003) Dual effects of intermittent or continuous administration on gene expression in the globus pallidus and subthalamic nucleus of adult rats with a unilateral 6-OHDA lesion. Synapse, 49, 246-260.
34. Nielsen, K.M. & Soghomonian, J. (2004) Normalization of glutamate decarboxylase gene expression in the entopeduncular nucleus of rats with a unilateral 6-hydroxydopamine lesion correlates with increased GABAergic input following intermittent but not continuous levodopa. Neuroscience, 123, 31-42.
35. Nutt, J.G. & Carter, J.H. (2000) Apomorphine can sustain the long-duration response to L-Dopa in fluctuating PD. Neurology, 54, 247-250.
36. Nutt, J.G., Carter, J.H., Leam, E.S. & Sexton, G.J. (2002) Evolution of the response to levodopa during the first 4 years of therapy. Ann. Neurol., 51, 686-693.
37. Nutt, J.G., Carter, J.H. & Woodward, W.R. (1995) Long-duration response to levodopa. Neurology, 45, 1613-1616.
38. Nutt, J.G. & Holford, N.H.G. (1996) The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann. Neurol., 39, 561-573.
39. Papa, S.M., Engber, T.M., Kask, A.M. & Chase, T.N. (1994) Motor fluctuations in levodopa-treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res., 662, 69-74.
40. Parkinson Study Group (2004) Levodopa and the progression of Parkinsons's Disease. N. Engl. J. Med., 351, 2498-2508.
41. Paxinos, G. & Watson, C. (1986) The Rat Brain in Stereotaxic Coordinates. Academic Press, New York.
42. Perier, C., Marin, C., Jiménez, A., Bonastre, M., Tolosa, E. & Hirsch, E.C. (2003) Effect of subthalamic nucleus or entopeduncular nucleus lesion on levodopa-induced neurochemical changes within the basal ganglia and on levodopa-induced motor alterations in 6-hydroxydopamine-lesioned rats. J. Neurochem., 86, 1328-1337.
43. Quattrone, A., Zappia, M., Aguglia, U., Branca, D., Colao, R., Montesanti, R., Nicoletti, G., Palmieri, A., Parlato & Rizzo, M. (1995) The subacute levodopa test for evaluating long-duration response in Parkinson's disease. Ann. Neurol., 38, 389-395.
44. Quik, M., Police, S., He, L., Di Monte, D.A. & Langston, J.W. (2000) Expression of D3 receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment. Neuroscience, 98, 263-273.
45. Ravenscroft, P., Chalon, S., Brotchie, J.M. & Crossman, A.R. (2004) Ropinirole versus L-Dopa effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia. Exp. Neurol., 185, 36-46.
46. Salin, P., Dziewczapolski, G., Gershanik, O.S., Nieoullon, A. & Raisman-Vozari, R. (1997) Differential regional enhances of long-term L-Dopa treatment on preproenkephalin and preprotachykinin gene expression in the striatum of 6-hydroxydopamine-lesioned rat. Mol. Brain Res., 47, 311-321.
47. Schallert, T., Fleming, S.M., Leasure, J.L., Tilerson, J.L. & Bland, S.T. (2000) CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology, 39, 777-787.
48. St-Hilaire, M., Landry, É., Lévesque, D. & Rouillard, C. (2003) Denervation and repeated L-Dopa induce a coordinate expression of the transcription factor NGFI-B in striatal projection pathways in hemiparkinsonian rats. Neurobiol. Dis., 14, 98-109.
49. St-Hilaire, M., Landry, E., Lévesque, D. & Rouillard, C. (2005) Denervation and repeated L-Dopa induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism. Neurobiol. Dis., 20, 450-460.
50. Stocchi, F., Berardelli, A., Vacca, L., Barbato, L., Monge, A., Nordera, G. & Ruggieri, S. (2003) Apomorphine infusion and the long-duration response to levodopa in advanced Parkinson's disease. Clin. Neuropharmacol., 3, 151-155.
51. Stocchi, F., Vacca, L., Berardelli, A., De Pandis, F. & Ruggieri, S. (2001) Long-duration effect and the postsynaptic compartment: study using a dopamine agonist with a short half-life. Mov. Dis., 16, 301-305.
52. 2A receptor mRNA in 6-hydroxydopamine-lesioned rats intermittently treated with L-Dopa. Synapse, 52, 218-222.
53. Van de Witte, S.V., Groenewegen, H.J. & Voorn, P. (2002) MK801 alters the effects of priming with L-Dopa on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons. Synapse, 43, 1-11.
54. Van Kampen, J.M. & Stoessl, A.J. (2000) Effects of oligonucleotide antisense to dopamine D1A receptor messenger RNA in a rodent model of levodopa-induced dyskinesia. Neuroscience, 98, 61-67.
55. Van Kampen, J.M. & Stoessl, A.J. (2003) Effects of oligonucleotide antisense to dopamine D3 mRNA in a rodent model of behavioural sensitization to levodopa. Neuroscience, 116, 307-314.
56. Vila, M., Marin, C., Ruberg, M., Jiménez, A., Raisman-Vozari, R., Agid, Y., Tolosa, E. & Hirsch, E.C. (1999) Systemic administration of NMDA and AMPA receptor antagonists reverses the neurochemical changes induced by nigrostriatal denervation in basal ganglia. J. Neurochem., 73, 344-352.
57. Westin, J.E., Andersson, M., Lundblad, M. & Cenci, M.A. (2001) Persistent changes in striatal gene expression induced by long-term L-Dopa treatment in a rat model of Parkinson's disease. Eur. J. Neurosci., 14, 1171-1176.
58. Winkler, C., Kirik, D., Björklund, A. & Cenci, M.A. (2002) L-Dopa-induced dyskinesia in the striatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis., 10, 165-186.
59. Zappia, M., Colao, R., Montesanti, R., Rizzo, M., Aguglia, U., Gambardella, A., Oliveiri, R.L. & Quattrone, A. (1997) Long-duration response to levodopa influences the pharmacodynamics of short-duration response in Parkinson's disease. Ann. Neurol., 42, 245-248.
60. Zeng, B.Y., Jolkkonen, J., Jenner, P. & Marsden, C.D. (1995) Chronic L-Dopa treatment differentially regulates gene expression of glutamate decarboxylase, preproenkephalin and preprotachykinin in the striatum of 6-hydroxydopamine-lesioned rat. Neuroscience, 66, 19-28.